Cidara Therapeutics (CDTX) Expected to Announce Quarterly Earnings on Thursday

Cidara Therapeutics (NASDAQ:CDTX) is anticipated to release its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect Cidara Therapeutics to post earnings of ($1.24) per share for the quarter. Interested persons can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, November 6, 2025 at 5:00 PM ET.

Cidara Therapeutics (NASDAQ:CDTX) last released its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.65) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.87) by $0.22. On average, analysts expect Cidara Therapeutics to post $-9 EPS for the current fiscal year and $-14 EPS for the next fiscal year.

Cidara Therapeutics Price Performance

Shares of CDTX stock opened at $104.68 on Thursday. The stock has a market capitalization of $2.65 billion, a price-to-earnings ratio of -9.41 and a beta of 1.33. The company’s fifty day simple moving average is $83.94 and its two-hundred day simple moving average is $54.19. Cidara Therapeutics has a 1 year low of $12.65 and a 1 year high of $121.21.

Insiders Place Their Bets

In other Cidara Therapeutics news, insider Nicole Negar Davarpanah sold 474 shares of the company’s stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $62.86, for a total value of $29,795.64. Following the transaction, the insider directly owned 31,418 shares in the company, valued at $1,974,935.48. This represents a 1.49% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.89% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of CDTX. California State Teachers Retirement System bought a new position in shares of Cidara Therapeutics in the second quarter worth approximately $51,000. Legal & General Group Plc purchased a new position in Cidara Therapeutics in the 2nd quarter worth approximately $73,000. Tower Research Capital LLC TRC increased its holdings in shares of Cidara Therapeutics by 66.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,556 shares of the biotechnology company’s stock worth $76,000 after buying an additional 623 shares during the last quarter. BNP Paribas Financial Markets raised its position in shares of Cidara Therapeutics by 10,594.1% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,818 shares of the biotechnology company’s stock valued at $89,000 after buying an additional 1,801 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of Cidara Therapeutics during the 2nd quarter valued at $146,000. Hedge funds and other institutional investors own 35.82% of the company’s stock.

Wall Street Analysts Forecast Growth

CDTX has been the subject of several recent research reports. JPMorgan Chase & Co. assumed coverage on Cidara Therapeutics in a research report on Friday, October 10th. They issued an “overweight” rating and a $200.00 price target for the company. Morgan Stanley began coverage on Cidara Therapeutics in a research note on Thursday, October 16th. They issued an “overweight” rating and a $190.00 target price for the company. Guggenheim set a $167.00 target price on Cidara Therapeutics and gave the company a “buy” rating in a report on Wednesday, September 24th. JMP Securities set a $173.00 price target on shares of Cidara Therapeutics and gave the stock a “market outperform” rating in a report on Friday, October 3rd. Finally, HC Wainwright restated a “buy” rating and issued a $150.00 price objective on shares of Cidara Therapeutics in a research report on Tuesday, October 21st. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $151.33.

About Cidara Therapeutics

Cidara Therapeutics, Inc, a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.